Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 4/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1280939 | 1.00 | EPHA2 (0.44) | EPHA2ERBB2EPHB4MEN1KMT2A | |
| SCHEMBL12469220 | 1.00 | EPHA2 (0.44) | EPHA2ERBB2EPHB4MEN1KMT2A | |
| SCHEMBL1280969 | 0.92 | EPHA2 (0.47) | EPHA2ERBB2EPHB4SLC5A1SLC5A2 | |
| SCHEMBL1279962 | 0.92 | EPHA2 (0.47) | EPHA2ERBB2EPHB4SLC5A1SLC5A2 | |
| SCHEMBL1280270 | 0.88 | SCN9A (0.48) | EPHA2ERBB2EPHB4SCN9A | |
| SCHEMBL1279850 | 0.85 | EPHA2 (0.46) | EPHA2ERBB2EPHB4SLC5A1SLC5A2 | |
| SCHEMBL15303273 | 0.84 | EPHA2 (0.42) | EPHA2ERBB2EPHB4SLC5A1SLC5A2 | |
| SCHEMBL15303274 | 0.84 | EPHA2 (0.42) | EPHA2ERBB2EPHB4SLC5A1SLC5A2 | |
| SCHEMBL1281254 | 0.83 | ERBB2 (0.42) | EPHA2ERBB2EPHB4SLC6A2SLC6A4 | |
| SCHEMBL1280369 | 0.83 | SLC6A2 (0.48) | EPHA2ERBB2EPHB4SLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722662-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-20130267494-A1 | 1,4-OXAZEPANE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-10 | — | — | US | disclosed |
| EP-2625170-A1 | 1,4-OXAZEPANE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2013-08-14 | — | — | EP | disclosed |
| WO-2012046882-A1 | 1,4-OXAZEPANE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267494-A1 | 1,4-OXAZEPANE DERIVATIVES | MAOB, SLC6A4, SLC6A2 | EPHA2 1397/4885ERBB2 1611/4885EPHB4 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.